The role of the dynorphin/κ opioid receptor system in anxiety

Ai HANG1, Yu-jun WANG2, Ling HE1, *, Jing-gen LIU2, *

1Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, China; 2Key Laboratory of Receptor Research, Shanghai institute of Materia Medica and Collaborative Innovation Center for Brain Science, Chinese Academy of Sciences, Shanghai 201203, China

Anxiety disorders are the most common and prevalent forms of psychiatric disease, although the biological basis of anxiety is not well understood. The dynorphin/κ opioid receptor system is widely distributed in the central nervous system and has been shown to play a critical role in modulating mood and emotional behaviors. In the present review, we summarize current literature relating to the role played by the dynorphin/κ opioid receptor system in anxiety and κ opioid receptor antagonists as potential therapeutic agents for the treatment of anxiety disorders.

Keywords: dynorphin; κ opioid receptor; stress; anxiety

Introduction

Anxiety is a recognized symptom of various anxiety disorders, with more than 3.6 million individuals in European countries suffering an anxiety disorder at some point in their lifetime[1]. The clinical anxiety disorders recognized in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) include the following: generalized anxiety disorder, obsessive compulsive disorder, panic disorder, acute and chronic posttraumatic stress disorder, and various phobias, including agoraphobia, social phobia, and specific phobia (e.g., fear of flying)[3]. Anxiety disorders, commonly occurring with depression and drug abuse, can be triggered or promoted by stress[3, 4]. The most widely used therapeutic agents for the treatment of anxiety disorders include selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, benzodiazepine anxiolytic and NMDA receptor modulators[5]. However, currently available anxiety disorder modulators are inadequate for patients because of the existence of “nonresponders” or unwanted side effects, such as ataxia, drowsiness, and impairment of cognition[6–8]. Increasing evidence indicates that the dynorphin/κ opioid receptor system plays an important role in the regulation of anxiety disorders. In this review, we describe existing data from preclinical studies using animal models to present an overview of the dynorphin/κ opioid receptor system in anxiety.

The dynorphin/κ opioid receptor system

κ Opioid receptors belong to the rhodopsin sub-family of the G protein-coupled receptor (GPCR) family. In the brain, κ opioid receptors are present primarily in the claustrum, cortex, hypothalamus, endopiriform nucleus, nucleus accumbens, caudate putamen, and substantial nigra[9–11]. Stimulation of κ opioid receptors results in the dissociation of G proteins into Gα and Gβγ subunits, in turn affecting a variety of effectors including adenylyl cyclase, potassium/calcium channels, phospholipase C and the p42/44 mitogen-activated protein kinase pathway[12]. Activation of the κ opioid receptor in vivo produces various effects, including analgesia/antinociception, psychomimesis, dysphoria/aversion, diuresis, antipruritic and blockade of psychostimulant effects[12]. In contrast, the activation of μ opioid receptors is known to induce euphoria and mediates positive reinforcement. Previous studies have demonstrated that κ opioid receptor agonists functionally attenuate cocaine-induced behavioral sensitization[13, 14], place preference[14, 15], and self-administration[16, 17]. These inhibitory effects of κ opioid receptor agonists on cocaine-induced abuse-related behaviors are achieved potentially through the inhibition of dopamine release from dopaminergic neurons[18, 19]. Dynorphin peptides, potent endogenous κ opioid recep-
tor ligands\textsuperscript{20}, consist of dynorphin A (Dyn A), dynorphin A(1-8), dynorphin B (Dyn B), α-neoendorphin (α-Neo), β-neoendorphin (β-Neo), leumorphin, and big dynorphin (Big Dyn), which contains both Dyn A and Dyn B)\textsuperscript{21} and have been found to modulate neuronal excitability and to regulate nociception, motivation, cognitive function and stress-induced mood disorders\textsuperscript{22}.

### Rodent models of anxiety

The validity of anxiety models rests on three criteria: face validity, predictive validity and construct validity\textsuperscript{35}. In the anxiolytic drug discovery field, the most commonly used rodent models include elevated plus-maze (EPM), light/dark box, social interaction, Vogel conflict, open field, ultrasonic distress vocalization, conditioned fear, Geller-Seifter conflict and stress-induced hyperthermia\textsuperscript{2}. Among these, EPM, light/dark box and open field have been main stay tests for many years. The details of these models and their uses in anxiety have been previously described\textsuperscript{2-34}. Pharmacological data involving different anxiety models are often inconsistent across studies. For example, mice with ablation of κ opioid receptors from brain dopamine neurons displayed anxiolytic effects in the open field and light/dark box tests but not in the EPM test\textsuperscript{26}. This discrepant result may be due to genetic and environmental influences\textsuperscript{29}. Therefore, it will be important to use multiple tests to obtain a broad understanding of the molecular mechanisms of anxiety and to develop new medications for the treatment of anxiety disorders.

### Role of the dynorphin/κ opioid receptor system in anxiety

Chronic stress may lead to anxiety and depression\textsuperscript{41}. Moderate to high levels of dynorphin mRNA and κ opioid receptors are expressed in regions of the brain that are stress-related in rodents, including the hypothalamic paraventricular nucleus (PVN), amygdala (AMY), hippocampus (Hip) and bed nucleus of the stria terminalis (BNST)\textsuperscript{11, 26, 27}, and stress exposure has been shown to increase endogenous dynorphin levels\textsuperscript{26}. A growing body of evidence reveals that the dynorphin/κ opioid receptor system plays an important role in stress\textsuperscript{28-31}.

#### κ Opioid receptor agonists and antagonists

Human studies show that selective κ opioid receptor agonists produce dysphoria, anxiety and abnormal behavior along with psychotomimesis at higher doses\textsuperscript{29}. The benzomorphan κ opioid receptor agonist MR2033 elicited dose-dependent dysphoric and psychotomimetic effects, which were antagonized by naloxone\textsuperscript{29}. This was consistent with work demonstrating that salvinorin A, a highly selective κ opioid receptor agonist, caused a certain degree of anxiety according to the state-trait anxiety inventory-S, a 20-item self-rating scale\textsuperscript{32}.

However, κ opioid receptor agonists exert biphasic effects on anxiety in rodents. Increasing evidence shows that selective κ opioid receptor agonists produce anxiety-like behaviors in the EPM test\textsuperscript{33-39}. These findings were further supported by findings that anxiolytic effects are produced by deficiencies in the κ opioid receptor system in mice. Mice lacking prodynorphin displayed increased anxiolytic parameters of explorative behavior in the open field as well as EPM and light-dark tests\textsuperscript{38}. Ablation of κ opioid receptors from brain dopamine neurons produced reduced anxiety-like behaviors in the open field and light-dark tests but not in the EPM test\textsuperscript{40}. In addition, intra-amygdala microinjection of dynorphin A increased anxiety-like behavior in the light-dark test\textsuperscript{41}. However, inconsistent with these observations is the finding that the κ opioid receptor agonist U50488 significantly increased time spent in open arms during the EPM test\textsuperscript{42, 43}. This is consistent with work demonstrating that U69593 and salvinorin A both produced anxiolytic effects in rodents\textsuperscript{44, 45}. Microinjection of U69593 into the infralimbic cortex reduced anxiety-like behavior in the EPM test\textsuperscript{46}. Kuzmin et al (2006) showed that big dynorphin, a prodynorphin-derived precursor peptide, induced anxiolytic-like behavior in mice in the EPM test\textsuperscript{47}. Whereas, deletion of the prodynorphin gene increased anxiety-like behaviors in the EPM and light-dark tests\textsuperscript{48}. Similarly, ablation of prodynorphin showed increased anxiety-like behaviors in zero-maze and startle-response tests\textsuperscript{49}. It must be noted that some lines of constitutive κ opioid receptor knockout (KO) mice did not display altered anxiety-like behaviors\textsuperscript{50, 51}. Discrepancies among these studies may be due to, but are not limited to, the use of specific genetic constructs for generating mutant mice, experimental paradigms, size of the apparatus, intensity of illumination, test conditions, animal strains, and lab specific basal stress levels. Although with these limitations and variables, the findings clearly demonstrate that the dynorphin/κ opioid receptor system is involved in anxiety-related behavior\textsuperscript{33-47, 49-51} (see Table 1 for a summary of current literature), but it is difficult to define the exact role of κ opioid receptor signaling because both anxiolytic- and anxiogenic-like effects are reported with κ opioid receptor agonists. Indeed, THC, a CB1 receptor agonist, microinjected at low doses in the prefrontal cortex and ventral hippocampus induced an anxiolytic-like response, while high doses caused an anxiogenic reaction\textsuperscript{52}. Considering that κ opioid receptors are widely expressed in the central nervous system\textsuperscript{11}, it is not surprising that specific brain regions (ie, prefrontal cortex, amygdala and hypothalamus) may have opposite and complementary roles in the regulation of anxiety by κ opioid receptors. Further studies are clearly needed to understand the mechanism involved in biphasic effects induced by κ opioid receptor agonists.

Although κ opioid receptor agonists present conflicting profiles in mood disorders, the administration of κ opioid receptor antagonists have been shown to exert consistent anxiolytic effects in different animal models\textsuperscript{34, 37-39, 53-60} (see Table 2 for a summary of the current literature). The κ opioid receptor antagonists nor-BNI and JDTic increased open arm exploration in EPM tests and decreased conditioned fear in the fear-potentiated startle paradigm\textsuperscript{55, 60}. Similarly, DIPPA produced anxiolytic-like effects in both novelty-induced hypophagia and defensive burying tests\textsuperscript{57}. In addition, it was demonstrated that animals treated with GNTi displayed increased open arm exploration in the EPM test and increased center area explora-
Together, these studies suggest that κ opioid receptor antagonists may be particularly effective for the treatment of anxiety disorders [61, 62].

**Link between the dynorphin/κ opioid receptor system and corticotrophin-released factor**

The neuropeptide corticotrophin-release factor (CRF) plays a critical role in the stress response by its regulation of the hypothalamic-pituitary axis (HPA) and subsequent adrenocorticosteroid release [63]. CRF and dynorphin are co-expressed in the hypothalamus [64, 65] and central amygdala [66, 67]. CRF causes dynorphin release [68, 69] and dynorphin-dependent κ opioid receptor activation in several anxiety-related brain regions [30]. Land et al (2008) reported that CRF-induced anxiety-like behaviors were blocked by a κ opioid receptor antagonist [30].

Recent work further showed that the anxiogenic-like effects of CRF were triggered by CRF1-R activation of the dynorphin/κ opioid receptor system [30]. These results reveal a connection between CRF and the dynorphin/κ opioid receptor system [70] and support that the CRF-induced dynorphin/κ opioid receptor-dependent pathway is involved in the modulation of anxiety-like behaviors [62].

**Brain regions involved in κ opioid receptor-mediated anxiety**

The mesocorticolimbic dopamine (DA) system originates in the ventral tegmental area (VTA) and projects to the amygdala, BNST, nucleus accumbens, prefrontal cortex, and hippocampus [40, 71]. κ Opioid receptors are located on both the cell bodies and terminals of mesocorticolimbic DA neurons [72, 73]. Activation of κ opioid receptors leads to the inhibition of DA neurons in the VTA [74] and decreases DA release in regions that receive VTA input [75, 76]. κ Opioid receptor agonists produce dysphoria, anhedonia and depressive-like effects, which are partially mediated by decreased function of the mesocorticolimbic DA system [76, 77]. Recently, two lines of mice with mutations in the κ opioid receptor system were generated [24].

**Table 1.** Evidence that dynorphin/κ opioid receptors (KOPRs) play a diphasic role in anxiety disorders.

| Behavior | Activate dynorphin/ KOPRs system | KOPRs agonists/dynorphin/ gene abation | Paradigm/model | Outcome | Reference |
|----------|----------------------------------|------------------------------------------|----------------|---------|-----------|
| Anxiogenic | Yes | U50488 (ip, 10 mg/kg) | Elevated plus maze | Decreased open time | 33 |
| Yes | U50488 (ip, 10 mg/kg) | Elevated plus maze | Decreased open time | 34 |
| Yes | U50488 (ip, 5 mg/kg) | Elevated plus maze | Decreased open time | 35 |
| Yes | U50488 (0.1, 1, and 10 mg/kg) | Elevated plus maze | Decreased center time | 36 |
| Yes | U50488 (ip, 10 mg/kg) | Elevated plus maze | Decreased open time | 37 |
| Yes | U50488 (ip, 2.5 mg/kg) | Elevated plus maze | Decreased open time | 38 |
| Yes | Dynorphin A | Light-dark box | Decreased open time | 39 |
| No | Prodynorphin+/− | Elevated plus maze; Light-dark box | Increased anxiolytic parameters of explorative behavior | 38 |
| No | DAT-KORlox/lox | Open field; Light-dark box | Decreased anxiety-like behavior | 40 |
| Anxiolytic | Yes | U50488 (sc, 2.5 mg/kg) | Elevated plus maze | Increased open time | 43 |
| Yes | U50488 (sc, 2.5 mg/kg, in the losers) | Elevated plus maze | Increased open time | 42 |
| Yes | U69593 (Microinjections in the IL cortex) | Elevated plus maze | Increased open time | 46 |
| Yes | U50488 (ip, 10–1000 µg/kg) | Elevated plus maze | Increased open time | 44 |
| Yes | U69593 (ip, 100 µg/kg) | Elevated plus maze | Increased open time | 45 |
| Yes | Salvinorin A (sc, 0.001–1000 µg/kg) | Elevated plus maze | Increased open time | 47 |
| Yes | Big dynorphin | Elevated plus maze | Increased latency of first area change and decreased activity in the open part | 49 |
| Yes | Prodynorphin+/− | Zero-maze test; Startle-response test | 1. Increased latency of first area change and decreased activity in the open part | 49 |
| No effect | No | KOR−/− | Elevated plus maze; Light-dark box | Increased anxiolytic parameters | 50 |
| No | KOR−/− | Elevated plus maze; Light-dark box | Decreased center time | 51 |
is a constitutive κ opioid receptor knockout (KOR−/−), the other is a conditional knockout (DAT-KORlox/lox) in which κ opioid receptors are lacking in DA-containing neurons. Behavioral characterization demonstrated that DAT-KORlox/lox mice displayed reduced anxiety-like behaviors in the open field and light/dark box tests. These findings suggest that the activation of κ opioid receptors in the mesocorticolimbic DA system plays a key role in anxiety.

The amygdala, a target of VTA dopamine neurons, is critical for anxiety-related responses. Knoll et al (2011) found that the microinjection of κ opioid receptor antagonist into the basolateral amygdala (BLA) produced anxiolytic-like responses in the EPM test. The importance of the amygdala in anxiety has also been confirmed by other researchers who report that stress- or CRF-induced anxiety is mediated by dynorphin released in the BLA, which can be blocked by a local injection of the κ opioid receptor antagonist norBNI.

The dorsal raphe nucleus (DRN), the primary source of serotonin that sends projections to multiple forebrain limbic regions, is critical for regulating affective states and stress. Land et al (2009) demonstrated that the aversive properties of κ opioid receptor activation was encoded by DRN to NAc serotonergic projections because κ opioid receptor KO mice failed to develop κ opioid receptor agonist US0488-induced CPA; however, lentivirus expression of κ opioid receptors in the DRN restored the aversive response, whereas lentivirus expression of mutated κ opioid receptors that were unable to activate p38 MAPK in the DRN did not restore the aversive response. In addition to mediating the dysphoric responses of stress, p38 MAPK activation within the DRN has also been found to contribute to depressive-like and drug-seeking behaviors.

The locus coeruleus (LC) is one of the primary sources of norepinephrine (NE) in the forebrain. Dynorphin and κ opioid receptors are coexpressed within the LC on noradrenergic (NA) neurons. Previous reports have shown that both stress and CRF engage in LC NA cell firing. Ai-Hasani et al (2013) first reported that κ opioid receptors within the LC NA nuclei modulate the reinstatement of cocaine place preference through a noradrenergic mechanism. Because the LC-NE system is a critical stress response system, κ opioid receptor pathway interactions with the NA system may influence κ opioid receptor-mediated aversion and anxiety-like behaviors. Evidence supports a model in which the dynorphin/κ opioid receptor system and CRF coordinate in stress-induced anxiety behaviors. κ Opioid receptors and CRF are co-expressed in the hypothalamus and central amygdala. Both stress and CRF cause dynorphin-dependent κ opioid receptor activation in the BLA, nucleus accumbens, dorsal raphe and hippocampus. Recent evidence indicates that κ opioid receptors are expressed on the terminal of amygdala inputs to BNST, a brain region strongly involved in fear and anxiety. Thus, there is a considerable possibility that the dynorphin/κ opioid receptor system within these regions may play a role in anxiety.

**Table 2. Evidence that κ opioid receptor (KOPR) antagonists can prevent anxiety-like behaviors from preclinical studies.**

| Behavior          | Inactivate KOPR/system | KOPR antagonists           | Paradigm/model          | Outcome                        | Reference |
|-------------------|------------------------|---------------------------|-------------------------|--------------------------------|-----------|
| Anxiolytic        | Yes                    | norBNI (sc, 30 mg/kg)     | The defensive withdrawal test | Decreased the latency to leave the withdrawal box | 53        |
|                   | Yes                    | JDTic (ip, 10 mg/kg)      | Elevated plus maze      | Increased open time             | 54        |
|                   | Yes                    | norNI (ip, 10, 20 mg/kg)  | Elevated plus maze      | Increased open time             | 34        |
|                   | Yes                    | JDTic (BLA, 0–10 µg/side) | Elevated plus maze      | Increased open time             | 55        |
|                   | Yes                    | AZ-MTAB (sc, 30 µmol/kg)  | Elevated plus maze      | Increased open time             | 56        |
|                   | Yes                    | LY-DMPF (sc, 24 µmol/kg)  | Novelty-induced hypophagia | Decreased the latency to feed | 57        |
|                   | Yes                    | DIPPA (sc, 2.5, 5 mg/kg)  | Defensive burying test  | Decreased burying time          | 57        |
|                   | Yes                    | JDTic (sc, 1, 4, 8, 16 mg/kg) | Elevated plus maze      | Increased open time             | 58        |
|                   | Yes                    | norBNI (ip, 20 mg/kg)     | Elevated plus maze      | Increased open time             | 37        |
|                   | Yes                    | norBNI (ip, 10 mg/kg)     | Elevated plus maze      | Increased open time             | 59        |
|                   | Yes                    | norBNI (ip, 10 mg/kg)     | Open Field              | Increased center time           | 38        |
|                   | Yes                    | GNTI (ic, 3 nmol)         | Open Field              | Increased center time           | 38        |
|                   | Yes                    | norBNI (sc, 20 mg/kg)     | Elevated plus maze      | Increased open time             | 39        |
|                   | Yes                    | norBNI (ip, 3–30 mg/kg); | Elevated plus maze      | Increased open time             | 60        |
|                   |                       | JDTic (ip, 1-10 mg/kg)    | Fear-potentiated startle | Decreased conditioned fear      | 60        |

**Various stress paradigms differentially influence κ opioid receptor-induced responses**

Previous studies implicate stress activation of the κ opioid receptor in increased anxiety behaviors, dysphoric responses, and potentiation of drug seeking behaviors. It has been reported that acute stress...
activates the hypothalamic-pituitary-adrenal (HPA) axis and influences amygdala CRF gene expression, which is a key mediator of the stress response. Acute stress has also been found to affect κ opioid receptor activation in the BLA and κ opioid receptor transcription in the PVN of the hypothalamus. Using an acute swim stress method, Bruchas et al. (2009) demonstrated that CRF1-R activation of the dynorphin/κ opioid receptor system in the BLA mediates anxiety-like behaviors. Moreover, recent work demonstrates that single acute swim stress-induced cocaine seeking reinstatement occurred via κ opioid receptor activation. Similar to acute stress, repeated exposure to stress also results in dynorphin release and subsequent κ opioid receptor activation. Following repeated swim stress, κ opioid receptor mRNA expression was regulated in a region-specific manner in the brain. In recent reports, exposure to repeated stress resulted in the dysregulation of κ receptor signaling in the DRN through a p38 MAPK-dependent mechanism. In this study, repeated swim stress significantly reduced κ opioid receptor-mediated G-protein gated inwardly rectifying potassium channel currents in serotonergic neurons postsynaptically, without affecting pre-synaptic excitatory transmission. The functional consequences of repeated stress exposure on κ opioid receptor-dependent behaviors have not been well investigated; however, several studies reveal that repeated swim stress-induced activation of the dynorphin/κ opioid receptor system potentiates nicotine conditioned place preference and cocaine rewarding effects. Chronic mild stress is a widely used animal model for inducing anxiety-like behavior; however, the significance of κ opioid receptors in chronic mild stress is unclear. Recently, Ai-Hasani et al. (2013) compared different types of exposure to stress (acute, sub-chronic, and chronic) to study the impact on κ opioid receptor-induced reinstatement. They found that following an acute swim stress, the activation of κ opioid receptors potentiated cocaine reinstatement; however, repeated swim stress and chronic mild stress blocked κ opioid receptor-induced cocaine or nicotine reinstatement. These findings indicate that various types of stress paradigms affect dynorphin/κ opioid receptor system-mediated reinstatement. Although these studies do not definitively prove that stress types differentially influence κ opioid receptor-mediated affective states, they do provide the basis for further investigation.

Ligand-directed signaling at the κ opioid receptor

Numerous studies support that GPCRs exist in multiple conformation states. Agonists can initiate distinct receptor conformations that produce distinct signaling cascades to mediate various behavioral effects. This concept is referred to as ligand-directed signaling or biased agonism. It has been recognized that biased μ opioid receptor agonists may be promising analgesics with less abuse potential, whereas biased κ opioid receptor agonists can be used for the treatment of pain and other disorders with less risk of convulsions. Ligand-directed signaling at the κ opioid receptor also has important implications because the activation of the κ opioid receptor produces analgesia with a low risk of addiction or dysphoria, unlike the action of the μ opioid receptor, which induces euphoria. κ Opioid receptor agonists activate a variety of kinase cascades including ERK1/2, JNKs, PKC, and p38 MAPKs. The link between κ opioid receptor ligand-selective signaling cascades and in vivo responses has not been fully characterized, but recent behavioral studies demonstrate that arrestin-dependent p38 activation is selectively involved in dysphoria induced by κ opioid receptor activation, whereas Gβγ-dependent signaling underlies analgesic responses. Bruchas et al. (2006) found that κ opioid receptors activate the p38 MAPK pathway through a GRK3- and arrestin-dependent mechanism. κ Opioid receptor activation of the p38 MAPK pathway in the DRN, a serotonergic nucleus, is important for κ opioid receptor agonist U50488-induced conditioned place aversion and stress-induced reinstatement of drug seeking. Further selective inactivation of p38 signaling in serotonergic neurons of the DRN blocked defeat-induced social aversion. Therefore, arrestin-dependent p38 activation is required for κ opioid receptor-mediated dysphoric and proaddictive effects. Together, these findings demonstrate that κ opioid receptor agonist-biased signaling exerts behavioral consequences. From a therapeutic perspective, signaling pathway-selective κ opioid receptor agonists may have clinical applications for the treatment of mood disorders. In contrast to κ opioid receptor agonists, κ opioid receptor antagonists such as norBNI, GNTI and JDtic have long durations of action and cause κ opioid receptor inactivation through a c-Jun N-terminal kinase (JNK)-dependent signaling cascade; the underlying mechanisms need to be elucidated.

Summary

The dynorphin/κ opioid receptor system has a wide range of biological effects, including affecting mood disorders, cognition and reward. Activation of the κ opioid receptor by agonists may have biphasic effects in anxiety-like behaviors. These inconsistent findings require further study to examine the underlying mechanism of the dynorphin/κ opioid receptor system in the neurobiology of anxiety. Another view based on preclinical studies is that κ opioid receptor antagonists produce profoundly consistent anxiolytic effects in animal behavioral models, although solid evidence from clinical studies is lacking. It is not fully understood how the κ opioid receptor blockade will eventually affect behavior. Answering this question may provide insights into the mechanism of anxiety. So far, the available κ opioid receptor antagonists have an extremely long duration of action. If shorter acting agents become available and are effective, κ opioid receptor antagonists may have therapeutic potential for the treatment of anxiety disorders.

Acknowledgements

This research was supported by grant 2013CB835100 (to Jing-gen LIU) from the Ministry of Science and Technology of China and by grants 81130087, 91232716 (to Jing-gen LIU) and 81401107 (to Yu-jun WANG) from the National Natural Science Foundation of China.
References

1 Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe — a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15: 357–76.

2 American Psychiatric Association (US). Diagnostic and statistical manual of mental disorders, 5th ed: DSM-V®. Arlington, VA: American Psychiatric Association; 2013.

3 van Praag HM. Can stress cause depression? Prog Neuro-Psychopharmacol Biol Psychiatry 2012; 36: 391–8.

4 Chiba S, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C, Kunugi H. Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 797–806.

5 Farb DH, Ratner MH. Targeting the modulation of neural circuitry for the treatment of anxiety disorders. Pharm Rev 2014; 66: 1002–32.

6 Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010; 71: 839–54.

7 Venlafaxine. Prescribing information. Pfizer/Wyeth Pharmaceuticals, Inc, Philadelphia 2012.

8 Alligulander C, Bandelow B, Hollander E, Montgomery SA, Nott DJ, Okasha A, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003; 8: 53–61.

9 Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 1987; 7: 2445–64.

10 Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci 1988; 11: 308–14.

11 Wang YJ, Rasakham K, Huang P, Chudnovskaya D, Cowan A, Liu-Chen LY. Sex difference in kappa opioid receptor (KOPR)-mediated behaviors and brain region KOPR level and KOPR-mediated guanosine 5’-O-[(3-[3H])thiotriphosphate] binding in the guinea pig. J Pharmacol Exp Ther 2011; 339: 438–50.

12 Liu-Chen LY. Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sci 2004; 75: 511–36.

13 Uki M, Mizutani M, Kameyama T. Opioid peptides selective for receptor types modulate cocaine-induced behavioral responses in mice. Nihon Shinkai Seishin Yakurigaku Zasshi 1994; 14: 153–9. Japanese.

14 Crawford CA, McDougall SA, Bolanos CA, Hall S, Berger SP. The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacol (Berl) 1995; 120: 392–9.

15 Shippenberg TS, LeFevour A, Heidbreder C. kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 1996; 276: 545–54.

16 Mello NK, Negus SS. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 1998; 286: 812–24.

17 Schenk S, Partridge B, Shippenberg TS. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacol (Berl) 1999; 144: 339–46.

18 Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988; 85: 5274–8.

19 Maisonneuve IM, Archer S, Glick SD. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extra-cellular dopamine in the nucleus accumbens of rats. Neurosci Lett 1994; 181: 57–60.

20 Chawkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 1982; 215: 413–5.

21 Schwarzer C. 30 years of dynorphin—new insights on its functions in neuropsychiatric diseases. Pharmacol Ther 2009; 123: 353–70.

22 Tejeda HA, Shippenberg TS, Henriksen R. The dynorphin/k-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 2012; 69: 857–96.

23 Ramos A. Animal models of anxiety: do I need multiple tests? Trends Pharmacol Sci 2008; 29: 493–8.

24 Van’t Veer A, Bechthold AJ, Onvani S, Potter D, Wang YJ, Liu-Chen LY, et al. Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity. Neuropsychopharmacology 2013; 38: 1585–97.

25 Wahlsten D, Bachmanov A, Finn DA, Crabbe JC. Stability of inbred mouse strain differences in behavior and brain size between laboratories and across decades. Proc Natl Acad Sci U S A 2006; 103: 16364–9.

26 Lin S, Boyd D, Lee N, Schwarzer C, Sainsbury A, Herzog H. Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain. Neuropeptides 2006; 40: 115–23.

27 Morris BJ, Haarmann I, Kempter B, Holtt V, Herz A. Localization of prodynorphin messenger RNA in rat brain by in situ hybridization using a synthetic oligonucleotide probe. Neurosci Lett 1986; 69: 104–8.

28 Nabeshima T, Katoh A, Wada M, Kameyama T. Stress-induced changes in brain Met-enkephalin, Leu-enkephalin and dynorphin concentrations. Life Sci 1992; 51: 211–7.

29 Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science 1988; 233: 774–6.

30 Land BB, Bruchas MR, Lemos JC, Xu M, Melief CJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin/k-opioid system. J Neurosci 2008; 28: 407–14.

31 McLaughlin JP, Martin-Popovici M, Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 2003; 23: 5674–83.

32 Gonzalez D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 2006; 85: 157–62.

33 Gillett K, Harshberger E, Valdez GR. Protracted withdrawal from ethanol and enhanced responsiveness stress: regulation via the dynorphin/k-opioid receptor system. Alcohol 2013; 47: 359–65.

34 Valdez GR, Harshberger E. Kappa opioid regulation of anxiety-like behavior during acute ethanol withdrawal. Pharmacol Biochem Beha 2012; 102: 44–7.

35 Smith JS, Schindler AG, Martinelli E, Gustin RM, Bruchas MR, Chavkin C. Stress-induced activation of the dynorphin/k-opioid receptor system in the amygdala potentiates nicotine conditioned place preference. J Neurosci 2012; 32: 1488–95.

36 Vunck SA, Snider SE, van den Oord EJCG, Beardsley PM. The kappa opioid receptor agonist, U50,488, exacerbates conditioned fear in mice. PASEB J 2011; 25: 617–20.

37 Harshberger E. Kappa opioid regulation of stress-related behavior. McNair Scholars J 2010; 14: 63–7.

38 Wittmann W, Schunk E, Rosskotten I, Gaburro S, Singewald N, Herzog H, et al. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 2009; 34: 775–85.

39 Wilm MD, Poveromo LB, Antapasis J, Herrera CM, Bolanos Guzman CA. Kappa-opioid system regulates the long-lasting behavioral adaptations induced by early-life exposure to methylphenidate. Neuropsychopharmacology 2009; 34: 1339–50.
Van’t Veer A, Carlezon WA Jr. Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology 2013; 229: 435–52.

Narita M, Kaneko C, Miyoshi K, Nagumo Y, Kuzumaki N, Nakajima M, et al. Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neurpsychopharmacology 2006; 31: 739–75.

Kudryavtseva NN, Gerrits MA, Avgustinovich DF, Tenditnikova MV, Van Ree JM. Modulation of anxiety-related behaviors by μ- and κ-opioid receptor agonists depends on the social status of mice. Peptides 2004; 25: 1355–63.

Privette TH, Tertian DM. Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacology 1995; 118: 44–50.

Braida D, Capurro V, Zani A, Rubinò T, Viganò D, Paroloro D, et al. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol 2009; 157: 844–53.

Wall PM, Messier C. U-69,593 microinjection in the infralimbic cortex reduces anxiety and enhances spontaneous alternation memory in mice. Brain Res 2000; 856: 259–80.

Kuzmin A, Madjid N, Tenerius L, Ogren SO, Bakalkin G. Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Neurpsychopharmacology 2006; 31: 1928–37.

Femenía T, Pérez-Rial S, Urigüen L, Manzanares J. Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAergic receptor subunits gene expression in the amygdala. J Psychopharmacol 2011; 25: 87–96.

Bilker-Gorzo A, Racz I, Michel K, Mauer D, Zimmer A, Klingmüller D. Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 2008; 33: 425–36.

Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 2000; 25: 195–200.

Simonin F, Valverde O, Smadja C, Slowé S, Kitchen I, Dierich A, et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 1998; 17: 886–97.

Rubino T, Guidali C, Viganò D, Realiini N, Valenti M, Massi P, et al. CB1 receptor activation in specific brain areas differently modulates anxiety-related behavior. Neurpsychopharmacology 2008; 54: 151–60.

Rogala B, Li Y, Li S, Chen XY, Kirouc GJ. Effects of a post-shock injection of the kappa opioid receptor antagonist norbinaltorphimine (norBNI) on fear and anxiety in rats. PLoS One 2012; 7: e49669.

Schank JR, Goldstein AL, Rowe KE, King CE, Marusich JD, Wiley JL, et al. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol 2012; 17: 634–47.

Knoll AT, Muschamp JW, Sillivan SE, Ferguson D, Dietz DM, Meloni EG, et al. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry 2011; 70: 425–33.

Peters MF, Zacco A, Gordon J, Maciag CM, Litwin LC, Thompson C, et al. Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol 2011; 661: 27–34.

Carr GV, Lucki I. Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats. Psychopharmacology 2010; 210: 295–302.

Jackson KJ, Carroll FI, Negus SS, Damaj MI. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology 2010; 210: 295–94.

Bruchas MR, Land BB, Lemos JC, Chavkin C. CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS One 2009; 4: e8528.

Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 2007; 323: 838–45.

Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res 2010; 1314: 56–73.

Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 2010; 1314: 44–5.

Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 1999; 46: 1167–80.

Roth KA, Weber E, Barchas JD, Chang D, Chang JK. Immunoactive dynorphin-(1–8) and corticotropin-releasing factor in subpopulation of hypothalamic neurons. Science 1983; 219: 189–91.

Meister B, Villar MJ, Ceccatelli S, Hokfelt T. Localization of chemical messengers in magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei: an immunohistochemical study using experimental manipulations. Neurosciences 1990; 37: 603–33.

Marchant NJ, Densmore VS, Osborne PB. Coexpression of prodynorphin and corticotropin-releasing hormone in the rat central amygdala: evidence of two distinct endogenous opioid systems in the lateral division. J Comp Neurol 2007; 504: 702–7.

Reyes BA, Drolet G, Van Bockstaele EJ. Dynorphin and stress-related peptides in rat locus coeruleus: contribution of amygdalar efferents. J Comp Neurol 2008; 508: 663–75.

Nikolarakis KE, Almeida OF, Herz A. Stimulation of hypothalamic beta-endorphin and dynorphin release by corticotropin-releasing factor (in vitro). Brain Res 1986; 399: 152–5.

Song ZH, Takemori AE. Stimulation by corticotropin-releasing factor of the release of immunoreactive dynorphin A from mouse spinal cords in vitro. Eur J Pharmacol 1992; 222: 27–32.

Van’t Veer A, Yano JM, Carroll FI, Cohen BM, Carlezon WA Jr. Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the kappa-opioid receptor antagonist JDTic. Neuropsychopharmacology 2012; 37: 2809–16.

Swanson LW. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 1982; 9: 321–53.

Svingos AL, Chavkin C, Colago EE, Pickel VM. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 2001; 42: 185–92.

Svingos AL, Colago EE, Pickel VM. Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. J Neurosci 1999; 19: 1804–13.

Ford CP, Beckstead MJ, Williams JT. Kappa opioid inhibition of somatodendritic dopamine inhibitory postsynaptic currents. J Neurophysiol 2007; 97: 883–91.

Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 1988; 244: 1067–80.

Carlezon WA Jr, Beguin C, DiNieri JA, Baumann MH, Richards MR, et al. Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol 2011; 661: 27–34.
Carlezon WA Jr, Thomas MJ. Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology 2009; 56: 122–32.

Maier SF, Watkins LR. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev 2005; 29: 829–41.

Land BB, Bruchas MR, Schattauer S, Giardino WJ, Alta M, Messinger D, et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci USA 2009; 106: 19168–73.

Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Kreibich A, Reyes BA, Curtis AL, Ecke L, Chavkin C, Van Bockstaele EJ. The locus coeruleus: a key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse. Brain Res 2010; 1314: 162–74.

Kreibich A, Reyes BA, Curtis AL, Ecke L, Chavkin C, Van Bockstaele EJ, et al. Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: a novel mechanism for regulating the central norepinephrine system. J Neurosci 2008; 28: 6516–25.

Reyes BA, Glaser JD, Magtoto R, Van Bockstaele EJ. Proopiomelanocortin colocalizes with corticotropin-releasing factor in axon terminals of the noradrenergic nucleus locus coeruleus. Eur J Neurosci 2006; 23: 2067–77.

Reyes BA, Johnson AD, Glaser JD, Commons KG, Van Bockstaele EJ. Dynorphin-containing axons directly innervate noradrenergic neurons in the rat nucleus locus coeruleus. Neurosciences 2007; 145: 1077–86.

Reyes BA, Chavkin C, Van Bockstaele EJ. Subcellular targeting of kappa-opioid receptors in the rat nucleus locus coeruleus. J Comp Neurol 2009; 512: 419–31.

Devilbiss DM, Waterhouse BD, Berridge CW, Valentino R. Corticotropin-releasing factor acting at the locus coeruleus disrupts thalamic and cortical sensory-evoked responses. Neuropsychopharmacology 2012; 37: 2020–30.

Maier SF, Watkins LR. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev 2005; 29: 829–41.

Land BB, Bruchas MR, Schattauer S, Giardino WJ, Alta M, Messinger D, et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci USA 2009; 106: 19168–73.

Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Kreibich A, Reyes BA, Curtis AL, Ecke L, Chavkin C, Van Bockstaele EJ. The locus coeruleus: a key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse. Brain Res 2010; 1314: 162–74.

Kreibich A, Reyes BA, Curtis AL, Ecke L, Chavkin C, Van Bockstaele EJ, et al. Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: a novel mechanism for regulating the central norepinephrine system. J Neurosci 2008; 28: 6516–25.

Reyes BA, Glaser JD, Magtoto R, Van Bockstaele EJ. Proopiomelanocortin colocalizes with corticotropin-releasing factor in axon terminals of the noradrenergic nucleus locus coeruleus. Eur J Neurosci 2006; 23: 2067–77.

Reyes BA, Johnson AD, Glaser JD, Commons KG, Van Bockstaele EJ. Dynorphin-containing axons directly innervate noradrenergic neurons in the rat nucleus locus coeruleus. Neurosciences 2007; 145: 1077–86.